A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. by Gross, Dolores et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Medical Oncology Faculty Papers Department of Medical Oncology
10-27-2011
A 2-step approach to myeloablative haploidentical
stem cell transplantation: a phase 1/2 trial
performed with optimized T-cell dosing.
Dolores Gross
Thomas Jefferson University, Dolores.Grosso@jefferson.edu
Matthew Carabasi
Thomas Jefferson University, Matthew.Carabasi@jefferson.edu
Joanne Filicko-O'Hara
Thomas Jefferson University, Joanne.Filicko-O'Hara@jefferson.edu
Margaret Kasner
Thomas Jefferson University, Margaret.Kasner@jefferson.edu
John L Wagner
Thomas Jefferson University, John.Wagner@jefferson.edu
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/medoncfp
Part of the Medical Immunology Commons, and the Oncology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
Recommended Citation
Gross, Dolores; Carabasi, Matthew; Filicko-O'Hara, Joanne; Kasner, Margaret; Wagner, John L;
Colombe, Beth; Cornett Farley, Patricia; O'Hara, William; Flomenberg, Phyllis; Werner-Wasik,
Maria; Brunner, Janet; Mookerjee, Bijoyesh; Hyslop, Terry; Weiss, Mark; and Flomenberg, Neal, "A
2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial
performed with optimized T-cell dosing." (2011). Department of Medical Oncology Faculty Papers.
Paper 10.
http://jdc.jefferson.edu/medoncfp/10
Authors
Dolores Gross, Matthew Carabasi, Joanne Filicko-O'Hara, Margaret Kasner, John L Wagner, Beth Colombe,
Patricia Cornett Farley, William O'Hara, Phyllis Flomenberg, Maria Werner-Wasik, Janet Brunner, Bijoyesh
Mookerjee, Terry Hyslop, Mark Weiss, and Neal Flomenberg
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/medoncfp/10
GROSSO et al.   T CELL OPTIMIZATION IN HAPLO-HSCT 
 
P a g e  | 1 
As submitted to: 
Blood 
And later published as: 
A TWO-STEP APPROACH TO MYELOABLATIVE HAPLOIDENTICAL 
STEM CELL TRANSPLANTATION: A PHASE I/II TRIAL PERFORMED 
WITH OPTIMIZED T CELL DOSING 
doi: 10.1182/blood-2011-07-365338 
October 27, 2011 
vol. 118 no. 17 
pp.4732-4739 
DOLORES GROSSO1, MATTHEW CARABASI1, JOANNE FILICKO-O’HARA1, MARGARET 
KASNER1, JOHN L. WAGNER1, BETH COLOMBE2, PATRICIA CORNETT FARLEY3, WILLIAM 
O’HARA4, PHYLLIS FLOMENBERG5, MARIA WERNER-WASIK6, JANET BRUNNER7, 
BIJOYESH MOOKERJEE1, TERRY HYSLOP1, MARK WEISS1 and NEAL FLOMENBERG1 
 
1Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pa. 19107; 2Department of 
Tissue Typing, Thomas Jefferson University Hospital, Philadelphia, Pa.19107; 3Stem Cell 
Processing Laboratory, Thomas Jefferson University Hospital; 4Department of Pharmacy, 
Thomas Jefferson University Hospital, Philadelphia, Pa. 19107; 5Department of Infectious 
Diseases, Thomas Jefferson University Hospital, Philadelphia, Pa. 19107; 6Department of 
Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, Pa. 19107; 7Center for 
International Blood and Marrow Transplant Research (CIBMTR), Milwaukee, Wi. 53226 
 
GROSSO et al.   T CELL OPTIMIZATION IN HAPLO-HSCT 
 
P a g e  | 2 
Corresponding Author: 
Dolores A. Grosso 
925 Chestnut Street, Suite 320 
Philadelphia, Pa. 19107 
dolores.grosso@jefferson.edu 
Phone: 215-955-4367 
Fax: 215-955-9641 
 
Category: Clinical Trials and Observations
GROSSO et al.   T CELL OPTIMIZATION IN HAPLO-HSCT 
 
P a g e  | 3 
Abstract 
Studies of haploidentical hematopoietic stem cell transplantation (HSCT) have identified 
threshold doses of T cells below which severe graft-versus-host (GVHD) is usually absent.  
However, little is known regarding optimal T cell dosing as it relates to engraftment, immune 
reconstitution, and relapse. To begin to address this question, we developed a 2 step 
myeloablative approach to haploidentical HSCT in which 27 patients conditioned with total body 
irradiation (TBI) were given a fixed dose of donor T cells (HSCT step 1), followed by 
cyclophosphamide (CY) for T cell tolerization. A CD34 selected HSC product (HSCT step 2) 
was infused after CY. A dose of 2 x108/kg T cells resulted in consistent engraftment, immune 
reconstitution, and acceptable rates of GVHD. Cumulative incidences of grade III-IV GVHD, 
non-relapse mortality and relapse-related mortality were 7.4%, 22.2%, and 29.6% respectively. 
With a follow-up of 28-56 months, 3 year probability of overall survival for the whole cohort is 
48% and 75% in patients without disease at HSCT. In the context of CY tolerization, a high, 
fixed dose of haploidentical T cells was associated with encouraging outcomes especially in 
good risk patients, and can serve as the basis for further exploration and optimization of this 2 
step approach.   
 
 
Presented in part in abstract form at the 51st annual meeting of the American Society of 
Hematology, New Orleans, La.  
 
ClinicalTrials.gov Identifier NCT00429143  
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Introduction 
Until recently, HLA haploidentical HSCT has often been associated with disappointing clinical 
outcomes limiting the widespread application of this approach. Higher rates of infection and 
relapse, two consequences of the T cell depletion required to prevent severe GVHD in 
recipients of HLA mismatched grafts, adversely impact long term survival particularly in patients 
transplanted late in their disease course. Because only a subset of appropriate transplant 
candidates has an HLA identical sibling or unrelated donor, the development of safer, more 
efficacious transplant approaches using haploidentical donors would provide potential transplant 
options for patients who lack well-matched donors.  
 
Based on murine models, clinical approaches to haploidentical transplantation initially relied on 
aggressive T cell depletion techniques.  Ex-vivo T cell depletion with soy bean agglutinin and E 
rosetting or the use of monoclonal antibodies such as T10B9 resulted in marrow products 
containing T cell doses in the range of 104 to 105 T cells/kg of recipient body weight. This 
degree of T cell depletion was associated with the attenuation of severe GVHD and provided 
consistent engraftment, particularly when anti-thymocyte globulin (ATG) was also 
administered.1,2  The correlate of a high degree of T cell depletion to avoid GVHD is delayed 
post-transplant immune recovery,3-9 mortality from infection and relapse,1,10-16 and higher rates 
of graft rejection as compared to T cell-containing regimens.17 Ruggeri and colleagues18 
demonstrated that the higher relapse rates associated with T cell depletion can be moderated in 
part by maximizing natural killer (NK) cell alloreactivity.  However, infectious mortality still 
remains an obstacle to long term survival even with this approach. 
 
Much of the data regarding the permissible content of T cells in the donor innocula was 
necessarily based on the correlation between T cell doses and the development of GVHD as 
opposed to immune reconstitution.  Severe GVHD was infrequent to absent with T cell doses of 
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less than 1x 105/kg in adults undergoing matched sibling HSCT 19 and with less than 5 x 104/kg 
in children undergoing haploidentical HSCT.20 Huang et al.21 reported encouraging rates of 
disease-free survival but a cumulative incidence of chronic GVHD that exceeded 50% when a 
median T cell dose of 2.4 x 108/kg was administered with ATG to recipients of haploidentical 
HSCT utilizing combined blood and marrow products from recombinant human granulocyte 
colony-stimulating factor (G-CSF) primed donors.    
 
The use of T cell add-back,22 selective lymphocyte depletion of donor grafts,23,24 and preemptive 
DLI 25, 26 are strategies used after T cell depleted haploidentical HSCT to preserve or restore the 
beneficial immune reconstituting effects of T cells.  Another approach involves the use of post-
transplant CY after non-myeloablative marrow grafts from haploidentical donors to preferentially 
delete activated lymphocytes as opposed to a non-selective depletion of all CD 3+ T cells. 27-29  
In one report,28 there were low infectious rates and little significant GVHD associated with the 
infusion of donor products  containing a mean number of 4.2 x 107/kg T cells.  Despite the use 
of these relatively high T cell-containing products, the rejection rate of 13% was higher, and the 
disease free survival rate was lower, than that reported by Huang et al.21 possibly due to the 
administration of comparatively less T cells, the use of a non-myeloablative conditioning 
regimen, or a combination of the two.   
 
These trials demonstrate that outcomes after haploidentical HSCT can be influenced by the 
dosing, timing, and treatment of donor T cells. Potential barriers to further progress include the 
lack of consistency in T cell dosing from which to compare and optimize outcomes and 
methodologies to deliver consistent T cell doses at the time of HSCT. An ideal approach would 
maximize the number of “safe”, non-alloreactive T cells, avoiding the problems of GVHD while 
preserving the beneficial effects of T cells with regard to engraftment, infectious complications, 
and relapse.  Moreover, while murine models of transplantation virtually always administer a 
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fixed dose of T cells to produce more consistent immunologic outcomes, human HSCT grafts 
contain a more highly variable number of passenger lymphocytes.  
 
We therefore developed a 2 step myeloablative approach to haploidentical HSCT in which our 
primary goal was to provide a fixed, and ideally maximized, dose of T cells in the context of CY 
tolerization. Myeloablative rather than reduced intensity conditioning was used to provide more 
treatment intensity to high-risk patients.  In the setting of myeloablative conditioning, we wished 
to maximize the number of T cells which could be safely administered and to use the higher 
number of stem cells which can be obtained from peripheral blood rather than marrow to avoid 
rejection.  Because there was no data regarding T cell dosing with CY tolerization in a 
myeloablative setting, the trial was designed as a phase I/II study in which an optimal dose of T 
cells would be initially determined, based on the incidences of graft rejection and of GVHD.  The 
goal of the phase II part of the study was to assess whether this optimized dose of 
cyclophosphamide-tolerized T cells would result in rapid immune constitution and low rates of 
severe infection, rejection, relapse, and significant GVHD, thus resulting in improved overall 
survival.   
 
Methods 
The 2 step transplant regimen 
Patients received 12 Gy of TBI administered in 8 fractions over 4 days on days -9 to -6.  After 
the last fraction of TBI, a DLI product was administered to deliver a specific dose of donor CD3+ 
T cells (see below) representing step one (the lymphoid portion) of the transplant.  Days -5 and -
4 were rest days. CY 60 mg/kg/day was given on days -3 and -2. Tacrolimus and 
Mycophenolate Mofetil were initiated on day-1 for GVHD prophylaxis.  A CD 34 selected donor 
stem cell product was infused on day 0, representing step two (the stem cell portion) of the 
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transplant. Granulocyte-macrophage colony stimulating factor (GM-CSF) 250µg/m2 was begun 
on day +1.  No steroids were permissible until after the second dose of CY.  In the absence of 
GVHD, Mycophenolate Mofetil was discontinued on day 28 after HSCT and a tacrolimus taper 
was initiated by day +60.   
 
Study design and endpoints 
The primary endpoint of the phase I part of the study was to determine the optimal (or maximum 
feasible) dose of CD3+ T cells that could be given with CY tolerization that would result in 
reliable engraftment without significant GVHD.  After review of T cell numbers in allogeneic 
peripheral stem cell products at our institution, we hypothesized that 2 x 108 CD3+ cells/kg 
would produce consistent engraftment and started the trial at that dose.  The study design was 
such that the dose of T cells would be escalated if excessive graft failure was observed or 
decreased if excessive GVHD was observed.  If excessive graft failure and GVHD were both 
observed at the same T cell dose, the study would close.  The study was also designed to close 
if, after 4 dose adjustments (up or down) an appropriate T cell dose could not be identified.  
Once a dose was identified where 6 patients achieved successful engraftment without 
significant (grade III/IV) GVHD, the phase I part of this protocol would close, and subsequent 
patients would be treated at this dose in the phase II portion of the trial.   
 
Since our goal was to develop a regimen that allowed haploidentical HSCT to be performed with 
low treatment related mortality (TRM) and since we anticipated a high relapse rate in the high 
risk patients likely to enter such a trial, the primary endpoint of the phase II part of the trial was 
demonstrate an overall survival of ≥ of 30% at 6 months. Secondary endpoints included the 
assessment of engraftment rates, immune reconstitution and infection, and incidence and 
severity of GVHD.  
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Recipient consent, eligibility, donor selection 
Written informed consent was obtained for all of the patients in accordance with the Declaration 
of Helsinki. The study was approved by the Institutional Review Board of Thomas Jefferson 
University.  Patients were eligible for inclusion if they had received front-line therapy for their 
disease, were without an available genotypically identical related donor, had an available 
related donor that was mismatched for > 2 HLA antigens  (HLA-A, B, C, DRB1) in the GVH 
direction, had adequate organ function as defined by a serum creatinine of ≤ 2.0 mg/dl or 
creatinine clearance of > 40 ml/min, pulmonary diffusion capacity > 45% (corrected for 
hemoglobin), and cardiac ejection fraction > 45%, had a Karnofsky Performance Status > 70%, 
were HIV negative, were not pregnant, and had no other active malignancies. Donors were 
selected to try to maximize anti-host alloreactivity based on factors such as a higher degree of 
HLA mismatch or the presence of KIR mismatches.  
 
Collection of cells, graft characteristics and processing 
Donors underwent apheresis on days -7 and -6 to collect the DLI product. The desired dose of 
CD 3+ cells was infused without manipulation after the last fraction of TBI on D-6.  After  
collection of the DLI product, donors received subcutaneous injections of G-CSF, 5 µg/kg BID 
on days -5 through -1, and underwent apheresis for hematopoietic stem cells (HSC) on days -2 
and -1. The HSC product underwent CD 34 selection using the Isolex 300i magnetic cell 
selection system (Baxter) followed by treatment with muromonab-CD3 (OKT-3 Ortho-Biotech) to 
decrease residual T cell amounts after selection.  The product was washed after OKT-3 
incubation prior to infusion to ensure that any infused OKT-3 was cell bound and that free OKT-
3 was not administered.  Processing and infusion of the HSC product occurred on day 0.  
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Definitions 
White cell engraftment was defined as an absolute neutrophil count (ANC) of > 0.5x109/L for at 
least 3 consecutive days post-transplant. Platelet engraftment was defined as a platelet count of 
> 20,000/µl without transfusion for the 7 preceding days. Toxicities were graded using National 
Cancer Institute (NCI) criteria (Common Toxicity Criteria). Acute GVHD was scored based on 
the Glucksberg system.30 Grades III-IV GVHD was termed “severe” GVHD.  Chronic GVHD was 
based on the National Institutes of Health Consensus Criteria.31  
 
Post-transplant supportive care 
Patients were monitored weekly with a quantitative CMV PCR assay performed on blood 
samples. If the test became positive, patients were pre-emptively treated with foscarnet or 
valganciclovir. Patients were given intravenous gamma globulin therapy every 3 to 4 weeks until 
IgG levels returned to the normal range.  
 
Statistical analysis 
The phase I portion of the trial was based on a continual reassessment method and the final T 
cell dose was determined based on the observed clinical outcomes as described above.  Six 
month survival was estimated using the Kaplan-Meier method (SPSS software, version 12).  
Cumulative incidence of grades II-IV GVHD, grades III-IV GVHD, engraftment, and relapse were 
all calculated with death as a competing risk using R v 2.11.1.   
 
Results 
Patients 
A total of 27 patients, median age of 52 years (range 19-67) with high risk hematologic 
malignancies were treated between the years of 2006 and 2009.  Patient, donor, and disease 
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characteristics are listed in Table 1. Patients and donors were mismatched for 2 (n = 2), 3 
(n=11), or 4 (n=13) HLA-A, B, C, or DR antigens in the GVHD direction.  A single patient with 
zero mismatches in the GVH direction and 4 mismatches in the host-versus-graft (HVG) 
direction because of HLA homozygosity was treated on the trial.   
 
T cell dose (transplant step 1) and subsequent in vivo alloreaction 
The initial T cell dose in this trial was 2 x 108 CD 3+ cells/kg.  This dose resulted in consistent 
engraftment and acceptable rates of severe GVHD.  Consequently, no dose escalation or de-
escalation was performed and all study patients received this dose except for one patient whose 
donor product contained only 1.7 x 108 T cells despite two days of apheresis. This patient 
engrafted and did not develop significant GVHD.   
 
Unexpectedly, patients developed fever (median temperature 103.8◦F) within 24 hours of the 
DLI.  Virtually all patients developed diarrhea coincident with or shortly after onset of the fever. 
Approximately 25% of patients developed rash in the same time frame.  Two of the patients who 
developed a rash and diarrhea in this time frame underwent biopsies which showed 
histopathologic evidence of GVHD. Fever and diarrhea were resistant to antipyretics and other 
supportive measures. However, in all cases, these symptoms abated after the second dose of 
CY.  A typical fever curve is shown in Figure 1.   
 
CD34 dose (transplant step 2) and engraftment 
CD34 and residual CD3 content of the second step of the graft is summarized in Table 2.  Two 
patients died before engraftment could be evaluated.  One patient with a flare of Crohn’s 
disease the week prior to HSCT (GVH direction mismatches = 0) developed hypotension and 
adult respiratory distress syndrome shortly after transplant.  He died on day +9 from a 
presumed bowel event related to his Crohn’s disease.  A second patient died of respiratory 
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syncytial virus pneumonitis (GVH direction mismatches = 3) on day +1. These two patients were 
evaluated for toxicity only.   
 
Twenty-three of the remaining 25 patients had full donor engraftment.  Neutrophil recovery 
occurred at a median of 12 days (range = 9-15) and platelet recovery occurred at a median of 
20.5 days (range = 15-46).  Cumulative incidence of engraftment for neutrophils and platelets 
was 85.2% and 74.1% respectively (Figure 2). Two multiparous females with multiple HLA 
antibodies rejected grafts from their daughters.  The first patient had an HLA class I anti-donor 
antibody and was successfully engrafted using a reduced intensity conditioning regimen and an 
alternate haploidentical donor.  The second patient demonstrated an HLA class II anti-donor 
antibody. This patient, who had no suitable alternate donor, was given 4 doses of Rituximab and 
apheresis followed by a reduced intensity conditioning regimen and was successfully engrafted 
using the original donor. Both patients who rejected their transplants had markedly different 
temperature curves as compared to those who successfully engrafted, with an earlier 
appearance of the initial temperature rise but a far milder fever later in the course. Their fever 
curves were more typical during their second transplants.  The fever curves of these patients 
are shown in Figure 1.  
 
TRM 
There were three deaths due to multi-organ failure.  These included the patient with a flare of 
Crohn’s disease described above.  The other 2 deaths occurred in the patients who experienced 
primary graft failure.  Although these patients were subsequently successfully engrafted, both 
died of multi-organ failure presumably due to the combined toxicities of the conditioning 
regimens used for two transplants in rapid succession.   
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Infection and immune reconstitution  
Three of 27 patients (11%) died of infection (bacterial sepsis with subsequent brain abscess-1, 
progression of pre-existing fungal pneumonia-1, RSV pneumonia-1) during the transplant 
admission.   
 
Sixteen patients alive and without evidence of recurrent disease at 6 months post HSCT were 
analyzed with regard to their immune reconstitution.  Their median CD3+/CD4+ cell count at day 
+28 was 33.6 cells/µl (range 11.5-171.8), rising to a median of 104.6 cells/µl (range 10-403.27) 
at day +100.  The median CD3+/CD8+ cell count at day +28 was 28.7 cells/µl (range 3.83-
160.09), rising to 151.3 cells/µl (range 2.31-2379.8) at day 100.  Lower CD3+/CD4+ and 
CD3+/CD8+ counts were associated with the use of corticosteroids for GVHD.  The CD3+/CD4+ 
and CD3+/CD8+ counts for these patients are shown in Figure 3.  Patients treated earlier in the 
trial who developed GVHD were treated more aggressively and appeared to have slower CD4 
count recovery.   There was no consistent pattern to CD4/CD8 ratios, although several patients 
developed very elevated CD3+/CD8+ counts at the time of infections. 
 
No patient died of complications related to CMV reactivation, although the majority of patients 
who were CMV seropositive developed evidence of reactivation (15 of 18) whether their donor 
was CMV seropositive or not. There were no cases of CMV tissue infection.   
  
GVHD 
None of the 25 evaluable patients died from GVHD.  Only 2 of 25 (8%) patients developed 
severe acute GVHD.  One patient developed steroid responsive grade III intestinal GVHD and 
one patient, having previously developed stage III skin GVHD which resolved with steroids and 
photopheresis, later developed grade IV liver GVHD which responded to treatment with OKT-3.  
Fourteen others developed grade II skin GVHD, with the majority of these patients (11) having 
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stage III skin disease only without evidence of GVHD in the liver or GI tract.  Their skin GVHD 
responded to steroids (n=8) or steroids plus photopheresis (n =3).   Three patients had grade I 
GVHD responding primarily to topical steroids.  Four of 25 evaluable patients (16%) developed 
chronic GVHD, score 1. Cumulative incidences of grades II-IV and grades III-IV GVHD were 
59.2% and 7.4%, respectively (Figure 4). 
 
Cumulative incidence of non-relapse mortality (NRM) at the time of the most recent follow-up 
was 22.2% (Figure 5).    
 
Relapse and overall survival  
Relapsed disease was the primary cause of death in patients treated on this trial.  Eight of 25 
patients (32%) experienced a relapse of their malignancies 49-327 days post HSCT. Cumulative 
incidence of death due to relapse (RRM) was 29.6% (Figure 5).  Six of 13 patients with active 
malignancy at the time of HSCT subsequently relapsed, while only two of 12 patients who 
underwent transplant while in remission relapsed afterwards. All patients who relapsed 
ultimately died from their malignancy, and all patients who are alive are at least 28 months post 
HSCT without evidence of their disease.   
 
Seventeen of 27 patients (63%) were alive 6 months after their transplant, satisfying the primary 
endpoint of the trial.  Kaplan-Meier estimate of overall survival was 54% at 1 year and 48 % at 3 
years (median follow up 40 months, range 28-56 months).  Patients without disease at the time 
of HSCT fared better with a projected OS of 75% at 3 years. Survival curves are shown in 
Figure 6.  All surviving patients remain in CR and have been followed for a minimum of 24 
months post-transplant.   
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Discussion 
Our goals in developing this 2 step regimen were: to develop a myeloablative regimen for 
haploidentical HSCT that could be administered to patients with refractory or relapsed 
hematological malignancies  initially, but would subsequently be appropriate for high risk 
patients earlier in their disease course who lacked other donor options; to avoid exposure of 
newly transplanted HSCs to high dose CY; to utilize peripheral blood rather than marrow as the 
stem cell source; and to fix and maximize the number of CD3 cells patients would receive in an 
effort to produce consistent outcomes following transplantation.  Of these, we considered the 
standardization of the CD3 dose to be the most essential.  Every animal transplant model 
carefully controls and fixes CD3 content, yet this is rarely done in clinical transplantation with the 
exception of trials of T cell depletion where the focus is often on a T cell threshold rather than a 
dose.  Essentially we believed that controlling the T cell dose was equally important to the 
outcome of transplant as prescribing specific doses of radiation and chemotherapy.  
 
The initially tested T cell dose of 2 x 108/kg was associated with prompt engraftment, little 
significant GVHD, and prompt immunological recovery and thus met our phase I criteria for an 
optimal dose of T cells within the context of these immunologic outcome measures.   In contrast 
to our own experience with T depleted haploidentical HSCT, deaths from infection at this T cell 
dose were very low despite a high rate of CMV reactivation.  In many patients, the reactivation 
was accompanied by a rise in CD3+/CD4+ and CD3+/CD8+ T cells, although the circulating T 
cells were not tested for CMV specificity.  In our prior experience with global T cell depletion, 
patients remained severely T lymphopenic throughout the course of viral infections.  With CY 
tolerization, CMV reactivation was typically rapidly controlled once immune suppression was 
tapered.  Twenty-one of twenty-seven patients (78%) survived until discharge and all 
subsequent deaths were related solely to relapsed disease and not TRM. 
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We did not anticipate the two rejections in patients with donor specific antibodies (DSA) 
especially in the context of a large T cell dose and the successful engraftment of a patient 
treated earlier in the trial with very broadly reactive anti-HLA antibodies, but who was without 
DSA. It is possible that the atypical early fevers in these two patients were a reflection of an 
antibody mediated lysis of the donor lymphocytes shortly after infusion which allowed residual 
host humoral and cellular immunity to reject the graft.  Rejection resulting from DSA was not 
well described at the time this trial was launched and a retrospective review of the literature 
revealed only one trial that described this phenomenon.32 Few additional reports have been 
published since this time and the cumulative experience, including our own, suggests that the 
presence of DSA is a significant risk factor for rejection of haploidentical grafts. 33,34  In the 
absence of DSA, over 60 patients treated with this 2 step approach either within this particular 
trial or subsequent to it have engrafted, demonstrating that without anti-donor antibodies, 
engraftment is consistent.    
    
The incidence of GVHD was higher in this trial versus that reported in other haploidentical trials 
where CY tolerization was used as GVHD prophylaxis.28  This likely reflects the 5 fold higher T 
cell dose that was administered, the aggressive taper of immune suppression, efforts to select 
the donor predicted to be most alloreactive amongst the available family members and  the 
more intensive conditioning regimen. Nonetheless, GVHD was primarily limited to skin and 
easily controlled with steroids or steroids and early photopheresis. Photopheresis is thought to 
ameliorate GVHD in part by increasing CD4+CD25+/FoxP3+ T regulatory cells (Tregs).35,36  The 
role of Tregs in controlling haploidentical GVHD after using this 2 step HSCT approach is an 
area of current inquiry. 
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Chronic GVHD was infrequent and was not severe.  This positive outcome likely contributed to 
the absence of late non-relapse mortality as most patients did not require chronic immune 
suppression. 
 
The febrile reaction, rash and diarrhea that resulted from the T cell infusion are reminiscent of 
the “haplo immunostorm” (HIS) described by Colvin and colleagues 37 when they infused similar 
doses of T cells following 2 Gy of radiation without other cytoreduction.  In that setting, HIS was 
thought to be mediated by a cytokine storm and not associated with GVHD or engraftment 
syndrome.  In our 2 step approach, the reaction resolved completely after two doses of CY and 
morphological analysis of skin and gut biopsies were consistent with GVHD.  In the Colvin et al. 
study, this phenomenon was observed when the CD3 dose reached 1 x 108/kg and was most 
pronounced at 2 x 108/kg, the dose utilized in this trial.  Similar febrile reactions were not 
reported by O’Donnell 29 and colleagues, probably because their median T cell dose was 5 fold 
lower than in our trial.   
 
We believe that during this in vivo alloreaction, donor lymphocytes contribute to the 
immunologic elimination of residual malignancy.  This is supported by the Colvin group’s 
observation that patients receiving haploidentical cellular therapy for resistant malignancy had 
clinical responses at the doses of T cells associated with HIS despite the minimal conditioning 
administered.   
 
One of the rationales for the two step approach described here was that donor lymphocytes 
would be exposed to CY while hematopoietic stem and progenitor cells would not.  While stem 
cells may be protected from mutagenic effects of CY due to their expression of aldehyde 
dehydrogenase, levels of this enzyme drop as cells diverge from the stem cell phenotype.  
Some current models of leukemogenesis posit that mutations occur in a post stem precursor 
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cell which, as a consequence, reacquires stem properties.  Whether secondary MDS or AML 
will emerge as problems in regimens where HSCs are exposed to CY remains to be seen.  The 
two step approach eliminates that issue, however big or small it may be.  It does require 4 days 
of apheresis for most donors (2 for DLI and 2 for HSC), but this has been well tolerated to date.   
 
The 52% and 48% one and three year overall survival rates observed in patients treated on this 
two-step regimen met the protocol criteria for an effective regimen.  Based on the current 
literature, the results appear comparable to outcomes in matched sibling and unrelated donor 
HSCT in similar high risk groups of patients. All six patients treated for lymphoid diseases, four 
patients with high-risk ALL and two patients with chemotherapy-resistant non-Hodgkin 
lymphoma, are disease-free 28 to 52 months post-transplant. Whether these favorable 
outcomes were due to the use of TBI in the conditioning regimen or to the large number of 
haploidentical T cells administered with this approach is unknown. If the latter is true, it may 
alter the spectrum of diseases in which strong graft-versus-tumor (GVT) effects are observed 
after haploidentical transplantation.    
 
Administration of the graft in two steps avoided the infusion of donor T cells that were skewed 
towards a TH2 phenotype since T cells were collected prior to administering G-CSF to the 
donors. Recognizing the high risk nature of the patients treated, we also administered GM-CSF 
rather than G-CSF after transplant in a further attempt to avoid G-CSF-induced polarization to a 
TH2 phenotype.38 Despite this strategy, relapsed disease in patients with AML or MDS was the 
primary cause of mortality.  Interestingly, six of the eight (75%) recipients that relapsed, 
including the only two patients who relapsed following transplantation while in remission, were 
mothers receiving grafts from their children.  Recent data supports a mechanism of long-lasting 
regulatory T cell mediated tolerance of maternal cells by offspring.39  While child to mother 
transplants have been associated with superior outcomes in other transplant settings,40  in our 
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limited population they were associated with higher rates of relapse.  It is possible that the 
outcomes associated with this donor-recipient combination are dependent on the particular 
disease state and transplant regimen which together will determine whether an increase or 
decrease in alloreactivity is likely to be beneficial or detrimental.     
 
Building on the platform of a large and consistent T cell dose, additional strategies can be 
explored with the potential to improve relapse rates in patients with advanced malignancies.  
Mayumi and Good demonstrated in murine models that the administration of CY 1-3 days after 
antigenic stimulation is the optimal time to establish allogeneic tolerance. 41 The optimal timing 
in man has not been directly studied.  It may be worthwhile to assess whether the interval 
between DLI and CY can be safely increased modestly in future trials as a means of allowing 
further immunologically mediated cytoreduction by the DLI prior to abrogation by CY.  Other 
drugs preferentially cytoxic to activated cells such as Melphalan 42,43  could potentially be 
introduced in place of CY using this 2 step approach without concerns about cytotoxicity toward 
hematopoietic stem cells.  This platform also allows the use of two haploidentical donors to 
further increase the GVT effect and eliminate the potential for leukemic escape due to 
uniparental disomy.44   
 
The results from this trial have been encouraging amongst patients undergoing transplant in 
remission with a follow up of in excess of two years for all patients.  The low regimen related 
mortality and high overall survival suggests that this approach can be extended to better risk 
patients earlier in their disease course and should be further studied in larger trials. 
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Table 1.  Patient Characteristics 
Number of Subjects 27 
Median Age, years (range) Recipient 52 (19-67) 
Donor 
39 (24-65) 
Sex  (M/F) 11/16 
  
Race White 19 
Black 
6 
Asian 
2 
  
Disease and Disease Status at HSCT  
AML CR1 with High Risk Features* 5 
AML CR2 2 
AML Primary Induction Failure 2 
AML in Resistant Relapse 7 
Biphenotypic Leukemia with Disease at HSCT 1 
ALL  CR2 (Ph-) 3 
ALL (Ph+) Morphologic Remission 1 
MDS  2 
NHL Chemotherapy Resistant 3 
Aplastic Anemia 1 
  
Previous Transplant 2 
Secondary Malignancy 2 
  
Recipient/Donor Transplant Combinations  
Sibling to Sibling / Parent to Child / Child to 
Parent 7 / 4 / 16 
  
CMV Serostatus Recipient (R) and Donor (D)  
R+/D+ 12 
R+/D- 6 
R-/D- 9 
  
# HLA Antigen Mismatches (GVH Direction) 
(A, B, Cw, DRB1)  
Four 13 
Three 11 
Two 2 
Zero† 1 
  
KIR Mismatches††   
KIR ligand missing in recipient but present in 
donor  
HLA-C Group 1  5 
HLA-C Group 2 4 
HLA- Bw4 1 
HLA-C and HLA Bw4 2 
No KIR Mismatch 15 
*  Based on cytogenetics, secondary disease, CNS/tissue involvement, or arising from MDS 
†
   Patient had 4 mismatches in HVG direction only and was counted for toxicity only 
† †
 Missing self as defined by Ruggeri et al.18 
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Figure 1.  Fever Curves after DLI Correlate with Clinical Events.  A 
typical temperature curve from an engrafting patient is shown in green.  Curves 
from the two patients with anti-donor antibodies who rejected their grafts are 
shown in red and blue.  The boundary between the febrile and afebrile ranges 
(100.4 °F) is shown by the horizontal solid black line.  The afebrile range is 
shaded gray.  Engrafting patients generally developed within 24 hours after DLI. 
The fever spikes persisted despite the use of acetaminophen and other comfort 
measures until after the second dose of CY. In the setting of anti-donor 
antibodies, the patients developed fever within a few hours of the DLI, rapidly 
defervesced and remained afebrile thereafter.   
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Table 2.  Graft Characteristics 
Step 1 Step 2 
CD3+/kg x108 
Median   (Range) 
CD34+/kg x106  
Median   (Range) 
Residual CD3+ Cells/kg 
 in CD 34+ Product x104 
Median  (Range) 
2.0  (1.7 in 1 patient, 
        2.0 in 26 patients) 3.6       (1.3-7.4) 0.51    (0.13-6.9) 
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Figure 2. Neutrophil and Platelet Engraftment. Cumulative incidences of 
neutrophil and platelet engraftment were 85.2% and 74.1% respectively. 
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Figure 3.  Immune Recovery after Haploidentical Transplant. 
CD3+/CD4+ cell counts (A) and CD3+/CD8+ cell counts (B) of 16 patients alive 
and disease-free at least 6 months post HSCT are illustrated. 
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Figure 4. Acute GVHD. Cumulative incidences of grades II-IV and III-IV GVHD 
were 59.2 % and 7.4% respectively. 
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Figure 5. Relapse and Non-Relapse Related Mortality. Cumulative 
incidences of RRM and NRM were 29.6% and 22.2% respectively.  
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Figure 6. Probability of Overall Survival. Survival for all 
patients in the trial is shown as the solid black line (48% 3 
year OS). Patients without marrow morphologic or 
radiographic evidence of disease at the time of transplant are 
shown with the dashed line (75% 3 year OS).  Patients with 
marrow or radiographic evidence of disease are shown in the 
dotted line (27% 3 year OS). 
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